ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
3,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
3,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
5,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
6,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
6,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
7,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
8,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
9,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
10,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
11,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
13,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
14,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
15,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
15,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
16,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
17,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
18,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
18,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
19,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
20,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
21,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
21,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
22,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
23,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
24,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
25,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
25,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
26,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
26,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
27,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
27,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
28,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
28,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
29,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
30,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
30,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
30,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
31,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
32,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
34,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
34,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
35,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
36,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
36,2,Cardiac murmur,Cardiac auscultatory investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
36,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
37,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
38,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
38,2,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
38,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
38,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
39,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
40,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
41,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
41,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
42,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
42,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
42,3,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
43,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
44,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
44,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
45,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
45,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
45,3,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
46,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
46,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
47,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
47,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
48,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
48,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
49,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
50,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
50,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
51,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
51,2,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
51,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
51,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
52,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
53,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
54,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
54,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
55,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
56,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
57,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
58,1,Periarthritis,Joint related disorders NEC,Joint disorders,Musc,N
59,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
59,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
60,1,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
61,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
62,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
63,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
63,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
63,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
63,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
64,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
65,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
66,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
67,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
68,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
69,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
69,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
69,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
70,1,Foreign body reaction,Inflammations,General system disorders NEC,Genrl,N
71,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
72,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
73,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
74,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
75,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
76,1,Device failure,Device issues NEC,Device issues,Prod,N
76,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
77,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
77,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
78,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
79,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
80,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
80,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
81,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
82,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
82,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
83,1,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
84,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
85,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
85,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
86,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
86,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
86,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
87,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
88,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
89,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
90,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
91,1,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
92,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
93,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
94,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
95,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
96,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
97,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
98,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
99,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
100,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
101,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
102,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
103,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
103,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
104,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
105,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
105,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
106,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
107,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
108,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
109,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
110,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
111,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
112,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
112,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
112,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
113,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
113,2,Headache,Headaches NEC,Headaches,Nerv,N
113,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
114,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
114,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
115,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
116,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
116,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
116,3,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
117,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
118,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
119,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
119,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
119,3,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
119,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
120,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
121,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
122,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
122,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
123,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
123,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
124,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
125,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
125,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
125,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
125,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
126,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
127,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
128,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
128,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
129,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
130,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
130,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
131,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
132,1,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
133,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
134,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
135,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
136,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
136,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
136,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
137,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
138,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
138,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
139,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
139,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
140,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
141,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
141,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
142,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
142,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
143,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
143,2,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
143,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
143,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
143,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
144,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
144,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
145,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
146,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
147,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
147,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
148,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
148,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
149,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
150,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
150,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
150,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
150,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
151,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
152,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
153,1,Multiple injuries,Non-site specific injuries NEC,Injuries NEC,Inj&P,Y
153,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
154,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
154,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
154,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
155,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
155,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
156,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
157,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
158,1,Device failure,Device issues NEC,Device issues,Prod,N
158,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
159,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
159,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
159,3,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
160,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
160,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
161,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
161,2,Feeling drunk,Feelings and sensations NEC,General system disorders NEC,Genrl,N
162,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
163,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
164,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
165,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
166,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
166,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
167,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
168,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
168,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
169,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
170,1,Headache,Headaches NEC,Headaches,Nerv,N
171,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
172,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
173,1,Device failure,Device issues NEC,Device issues,Prod,N
173,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
173,3,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
174,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
175,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
175,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
176,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
176,2,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
177,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
178,1,Asphyxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,Y
178,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
178,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
178,4,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
178,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
179,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
180,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
181,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
182,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
183,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
184,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
185,1,Polyneuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
186,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
187,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
188,1,Systemic lupus erythematosus,Lupus erythematosus (incl subtypes),Connective tissue disorders (excl congenital),Musc,Y
189,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
190,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
191,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
192,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
193,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
194,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
195,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
195,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
196,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
197,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
198,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
199,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
199,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
200,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
201,1,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
202,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
203,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
204,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
205,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
205,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
206,1,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
207,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
207,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
208,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
208,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
209,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
210,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
211,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
211,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
212,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
212,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
213,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
214,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
214,2,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
214,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
215,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
216,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
217,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
218,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
219,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
219,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
219,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
219,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
220,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
220,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
221,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
222,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
223,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
224,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
224,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
225,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
225,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
226,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
227,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
227,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
228,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
229,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
229,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
230,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
231,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
232,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
233,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
234,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
234,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
235,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
235,2,Scleroderma,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
236,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
237,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,Y
237,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
237,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
237,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
238,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
239,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
240,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
241,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
241,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
242,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
243,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
244,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
244,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
245,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
246,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
247,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
248,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
249,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
249,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
250,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
250,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
251,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
252,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
253,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
254,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
255,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
255,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
256,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
256,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
257,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
257,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
258,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
259,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
259,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
260,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
260,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
261,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
261,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
262,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
263,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
264,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
265,1,Erythema induratum,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
265,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
266,1,Headache,Headaches NEC,Headaches,Nerv,N
266,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
267,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
268,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
268,2,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
269,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
270,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
271,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
272,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
273,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
274,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
274,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
275,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
275,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
275,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
276,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
276,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
277,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
278,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
278,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
279,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
280,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
280,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
281,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
282,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
282,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
283,1,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
284,1,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
285,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
286,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
286,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
286,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
287,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
288,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
289,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
289,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
290,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
291,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
292,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
293,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
294,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
295,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
296,1,Glycosuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
296,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
297,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
298,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
298,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
299,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
300,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
300,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
301,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
302,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
303,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
303,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
304,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
305,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
305,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
305,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
305,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
306,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
307,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
308,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
309,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
310,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
311,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
312,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
313,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
313,2,Device failure,Device issues NEC,Device issues,Prod,N
313,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
314,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
314,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
314,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
315,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
316,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
317,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
317,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
318,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
319,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
319,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
319,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
320,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
321,1,Asphyxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,Y
321,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
322,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
322,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
322,3,Personality disorder,Personality disorders NEC,Personality disorders and disturbances in behaviour,Psych,N
323,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
324,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
325,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
326,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
327,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
328,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
329,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
330,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
331,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
332,1,Headache,Headaches NEC,Headaches,Nerv,N
333,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
334,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
335,1,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
335,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
336,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
337,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
338,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
339,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
340,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
340,2,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
341,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
341,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
342,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
343,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
344,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
345,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
346,1,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
346,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
347,1,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
347,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
348,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
349,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
349,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
350,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
351,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
352,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
352,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
353,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
353,2,Headache,Headaches NEC,Headaches,Nerv,N
353,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
353,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
353,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
354,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
355,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
356,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
357,1,Headache,Headaches NEC,Headaches,Nerv,N
357,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
358,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
359,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
360,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
361,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
362,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
363,1,Depersonalisation/derealisation disorder,Dissociative states,Dissociative disorders,Psych,N
363,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
364,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
364,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
365,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
365,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
366,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
367,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
367,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
368,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
369,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
370,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
371,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
372,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
373,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
374,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
374,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
375,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
375,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
376,1,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
377,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
378,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
379,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
380,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
381,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
382,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
383,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
384,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
385,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
386,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
387,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
388,1,Device failure,Device issues NEC,Device issues,Prod,N
389,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
390,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
391,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
392,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
393,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
394,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
395,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
396,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
397,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
397,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
397,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
398,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
399,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
400,1,Hyperkeratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
400,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
400,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
401,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
402,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
403,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
404,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
405,1,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
405,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
405,3,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
406,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
407,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
408,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
408,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
409,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
409,2,Headache,Headaches NEC,Headaches,Nerv,N
410,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
411,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
411,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
412,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
413,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
413,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
414,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
414,2,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
414,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
415,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
416,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
417,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
417,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
418,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
418,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
419,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
420,1,Acne,Acnes,Skin appendage conditions,Skin,N
420,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
421,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
421,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
421,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
421,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
422,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
423,1,Nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
423,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
424,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
425,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
426,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
427,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
428,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
429,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
429,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
430,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
431,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
432,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
433,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
433,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
433,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
433,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
433,5,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
434,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
434,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
435,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
435,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
436,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
437,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
437,2,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
438,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
439,1,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
440,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
440,2,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
441,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
441,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
442,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
442,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
442,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
443,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
444,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
444,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
445,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
445,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
446,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
447,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
447,2,Lactic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
448,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
449,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
450,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
451,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
451,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
452,1,Headache,Headaches NEC,Headaches,Nerv,N
452,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
453,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
453,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
453,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
453,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
453,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
453,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
454,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
455,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
456,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
457,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
458,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
459,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
459,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
460,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
461,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
462,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
463,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
464,1,Amyloidosis,Amyloidoses,Immune disorders NEC,Immun,N
464,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
465,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
465,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
466,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
467,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
467,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
468,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
469,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
469,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
470,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
470,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
471,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
471,2,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
471,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
472,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
472,2,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
473,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
474,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
474,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
475,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
475,2,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
475,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
475,4,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
475,5,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
475,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
476,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
477,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
478,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
478,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
479,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
480,1,Device failure,Device issues NEC,Device issues,Prod,N
480,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
481,1,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
482,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
482,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
483,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
483,2,Migraine,Migraine headaches,Headaches,Nerv,N
483,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
484,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
485,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
486,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
487,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
487,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
488,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
488,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
489,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
489,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
489,3,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
489,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
489,5,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
489,6,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
490,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
490,2,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
490,3,Cerebral disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
490,4,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
490,5,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
490,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
490,7,Food allergy,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
490,8,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
490,9,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
490,10,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
490,11,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
490,12,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
490,13,Pharyngeal disorder,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
490,14,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
491,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
492,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
492,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
493,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
494,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
494,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
494,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
495,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
495,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
496,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
496,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
497,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
497,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
497,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
498,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
499,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
500,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
501,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
501,2,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
501,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
501,4,Inappropriate affect,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
501,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
502,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
502,2,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
502,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
502,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
503,1,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
503,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
503,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
504,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
504,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
505,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
505,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
505,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
505,4,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
505,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
505,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
506,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
507,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
508,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
509,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
509,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
509,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
509,4,Headache,Headaches NEC,Headaches,Nerv,N
509,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
509,6,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
509,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
509,8,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
510,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
511,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
512,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
512,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
513,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
514,1,Pre-eclampsia,Hypertension associated disorders of pregnancy,Maternal complications of pregnancy,Preg,N
515,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
515,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
515,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
515,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
515,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
515,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
515,7,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
516,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
516,2,Nephrolithiasis,Renal lithiasis,Urolithiases,Renal,N
516,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
516,4,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
516,5,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
517,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
518,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
518,2,Device failure,Device issues NEC,Device issues,Prod,N
519,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
520,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
521,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
522,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
523,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
523,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
524,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
525,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
525,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
526,1,Brain stem syndrome,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
526,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
527,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
527,2,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
527,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
527,4,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
528,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
528,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
528,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
529,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
530,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
531,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
532,2,Joint contracture,Joint related disorders NEC,Joint disorders,Musc,N
532,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
533,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
534,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
534,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
535,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
536,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
536,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
536,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
536,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
537,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
537,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
538,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
539,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
539,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
539,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
539,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
539,5,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
540,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
541,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
541,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
541,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
541,4,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
541,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
542,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
542,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
543,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
543,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
543,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
544,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
545,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
545,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
545,3,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
546,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
547,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
547,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
547,3,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
547,4,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
547,5,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
547,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
547,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
547,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
547,9,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
547,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
547,11,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
547,12,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
547,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
548,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
548,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
549,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
549,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
550,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
551,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
552,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
552,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
553,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
553,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
553,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
554,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
554,2,Nosocomial infection,Infectious transmissions,Ancillary infectious topics,Infec,Y
554,3,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
554,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
555,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
556,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
556,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
557,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
557,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
557,3,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
557,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
558,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
558,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
559,1,Device failure,Device issues NEC,Device issues,Prod,N
559,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
560,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
561,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
561,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
561,3,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
562,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
562,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
563,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
564,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
565,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
565,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
565,3,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
565,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
566,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
566,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
566,3,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
566,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
566,5,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
566,6,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
566,7,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
566,8,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
567,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
567,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
568,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
569,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
569,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
569,3,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
569,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
569,5,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
569,6,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
569,7,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
569,8,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
569,9,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
569,10,Headache,Headaches NEC,Headaches,Nerv,N
569,11,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
569,12,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
569,13,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
570,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
570,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
571,1,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
571,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
571,3,Blood prolactin decreased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
571,4,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
571,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
571,6,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
571,7,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
571,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
571,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
571,10,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
571,11,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
571,12,Headache,Headaches NEC,Headaches,Nerv,N
571,13,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
571,14,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
571,15,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
571,16,Hypopituitarism,Anterior pituitary hypofunction,Hypothalamus and pituitary gland disorders,Endo,N
571,17,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
571,18,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
571,19,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
571,20,Pituitary infarction,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
571,21,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
571,22,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
572,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
572,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
572,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
572,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
572,5,Product residue present,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
573,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
574,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
574,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
574,3,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
575,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
575,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
576,1,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
576,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
577,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
577,2,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
577,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
578,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
578,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
578,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
578,4,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
578,5,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
579,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
579,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
579,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
580,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
580,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
580,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
580,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
580,5,Terminal state,General signs and symptoms NEC,General system disorders NEC,Genrl,N
581,1,Autoimmune disorder,Autoimmune disorders NEC,Autoimmune disorders,Immun,N
581,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
582,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
583,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
584,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
584,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
584,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
585,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
585,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
585,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
585,5,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
585,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
586,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
586,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
586,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
586,4,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
586,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
586,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
586,7,Headache,Headaches NEC,Headaches,Nerv,N
586,8,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
586,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
586,10,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
587,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
587,2,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
587,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
587,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
587,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
588,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
588,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
589,1,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
590,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
590,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
591,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
591,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
592,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
593,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
593,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
594,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
594,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
595,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
595,2,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
595,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
595,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
595,5,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
595,6,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
596,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
596,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
596,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
596,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
596,5,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
596,6,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
596,7,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
596,8,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
597,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
597,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
597,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
598,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
598,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
598,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
598,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
598,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
599,1,Device leakage,Device issues NEC,Device issues,Prod,N
599,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
600,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
601,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
601,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
601,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
601,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
602,1,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,Y
603,1,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
603,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
604,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
605,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
606,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
606,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
607,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
608,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
608,2,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
608,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
609,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
609,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
609,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
609,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
610,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
610,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
611,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
611,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
611,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
611,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
611,5,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
611,6,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
611,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
612,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
612,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
612,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
613,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
613,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
613,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
613,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
614,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
615,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
615,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
615,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
615,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
615,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
616,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
616,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
616,3,Injection site oedema,Injection site reactions,Administration site reactions,Genrl,N
617,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
618,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
619,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
619,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
619,3,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
620,1,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
621,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
621,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
621,3,Headache,Headaches NEC,Headaches,Nerv,N
621,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
621,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
621,6,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
621,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
622,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
622,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
622,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
623,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
623,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
624,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
624,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
624,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
625,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
625,2,Hyperinsulinaemic hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
625,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
626,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
626,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
626,3,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
627,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
627,2,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
628,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
628,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
629,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
629,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
629,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
629,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
630,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
631,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
631,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
631,3,Type I hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
632,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
633,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
633,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
634,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
635,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
635,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
636,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
636,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
636,3,Gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
636,4,Neonatal diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
637,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
638,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
638,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
639,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
639,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
639,3,Headache,Headaches NEC,Headaches,Nerv,N
639,4,Urine ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
640,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
640,2,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
640,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
640,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
640,5,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
641,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
642,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
643,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
644,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
644,2,Device failure,Device issues NEC,Device issues,Prod,N
644,3,Escherichia infection,Escherichia infections,Bacterial infectious disorders,Infec,N
645,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
645,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
646,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
646,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
646,3,Device failure,Device issues NEC,Device issues,Prod,N
647,1,Hypopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
648,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
648,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
649,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
649,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
650,1,Device issue,Device issues NEC,Device issues,Prod,N
650,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
650,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
650,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
650,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
651,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
651,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
652,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
652,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
653,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
654,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
654,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
654,3,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
654,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
654,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
654,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
655,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
655,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
655,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
656,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
656,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
657,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
657,2,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
658,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
658,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
658,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
659,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
659,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
660,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
660,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
660,3,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
661,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
662,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
663,1,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
664,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
665,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
666,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
666,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
667,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
667,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
668,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
668,2,Pituitary-dependent Cushing's syndrome,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
668,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
669,1,Acanthosis nigricans,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
669,2,Acrochordon,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
669,3,Acromegaly,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
669,4,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
669,5,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
669,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
669,7,Macroglossia,Tongue disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
669,8,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
669,9,Tooth disorder,Dental disorders NEC,Dental and gingival conditions,Gastr,N
670,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
670,2,Foetal macrosomia,Foetal growth complications,Foetal complications,Preg,N
670,3,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
671,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
671,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
671,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
672,1,Acromegaly,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
673,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
673,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
673,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
673,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
674,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
674,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
675,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
676,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
677,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
678,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
678,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
678,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
678,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
678,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
679,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
679,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
680,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
680,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
680,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
681,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
681,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
682,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
682,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
682,3,Polyhydramnios,Amniotic fluid and cavity disorders of pregnancy NEC,"Placental, amniotic and cavity disorders (excl haemorrhages)",Preg,N
683,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
684,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
684,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
685,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
685,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
685,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
686,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
686,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
687,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
688,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
688,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
689,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
689,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
690,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
690,2,Food aversion,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
690,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
690,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
690,5,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
690,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
690,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
691,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
692,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
692,2,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
692,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
692,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
693,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
694,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
694,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
694,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
695,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
695,2,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
695,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
696,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
696,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
696,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
696,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
697,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
697,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
698,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
698,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
699,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
699,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
700,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
700,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
700,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
701,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
701,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
701,3,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
701,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
702,1,Product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
702,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
703,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
703,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
704,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
704,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
705,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
705,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
705,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
705,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
705,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
705,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
706,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
706,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
707,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
707,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
707,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
708,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
708,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
708,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
709,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
709,2,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
709,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
709,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
710,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
710,2,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
711,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
712,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
712,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
713,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
713,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
714,1,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
715,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
715,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
716,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
716,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
717,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
717,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
717,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
717,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
717,5,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
718,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
718,2,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
719,1,Body mass index increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
719,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
719,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
719,4,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
720,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
720,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
720,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
720,4,Large intestinal ulcer,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
720,5,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
720,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
721,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
721,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
721,3,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
721,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
721,5,Peritonitis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
722,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
722,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
722,3,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
722,4,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
722,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
723,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
723,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
723,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
723,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
723,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
723,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
723,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
723,8,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
723,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
723,10,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
723,11,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
723,12,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
723,13,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
723,14,Impatience,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
723,15,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
723,16,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
723,17,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
723,18,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
723,19,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
723,20,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
723,21,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
723,22,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
723,23,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
723,24,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
723,25,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
723,26,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
723,27,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
723,28,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
723,29,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
724,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
724,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
724,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
725,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
725,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
725,3,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
725,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
725,5,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
725,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
726,1,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
726,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
727,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
727,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
727,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
728,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
729,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
729,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
729,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
730,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
731,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
732,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
733,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
734,1,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
734,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
734,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
735,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
736,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
737,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
738,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
739,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
740,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
741,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
742,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
743,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
744,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
745,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
746,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
746,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
747,1,Migraine,Migraine headaches,Headaches,Nerv,N
748,1,Bone cancer,Bone neoplasms malignant (excl sarcomas),Skeletal neoplasms malignant and unspecified,Neopl,N
748,2,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
748,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
749,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
749,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
749,3,Cerebral thrombosis,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
749,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
750,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
750,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
750,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
751,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
751,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
751,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
751,4,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
752,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
752,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
752,3,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
753,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
754,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
755,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
755,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
755,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
755,4,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
756,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
757,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
757,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
758,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
759,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
759,2,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
760,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
760,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
761,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
761,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
762,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
762,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
763,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
763,2,Headache,Headaches NEC,Headaches,Nerv,N
763,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
763,4,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
763,5,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
763,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
764,1,Vitreous floaters,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
765,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
765,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
766,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
767,1,Acute painful neuropathy of rapid glycaemic control,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
767,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
767,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
767,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
767,5,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
767,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
767,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
767,8,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
767,9,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
767,10,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
768,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
768,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
768,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
768,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
768,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
769,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
769,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
769,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
770,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
770,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
770,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
770,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
770,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
771,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
771,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
771,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
772,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
772,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
772,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
773,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
774,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
774,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
774,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
775,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
776,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
777,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
778,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
779,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
780,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
780,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
780,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
780,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
781,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
781,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
781,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
782,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
782,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
782,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
783,1,Appetite disorder,Appetite disorders,Appetite and general nutritional disorders,Metab,N
783,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
783,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
783,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
784,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
784,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
785,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
785,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
785,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
785,4,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
785,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
786,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
787,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
788,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
789,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
789,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
789,3,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
789,4,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
790,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
790,2,Pituitary-dependent Cushing's syndrome,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
790,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
791,1,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
792,1,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
792,2,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
793,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
794,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
794,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
794,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
794,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
794,5,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
794,6,Groin infection,Infections NEC,Infections - pathogen unspecified,Infec,N
794,7,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
794,8,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
794,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
794,10,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
794,11,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
795,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
795,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
795,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
795,4,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
796,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
796,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
796,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
796,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
797,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
798,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
799,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
799,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
799,4,Hyperglycaemic hyperosmolar nonketotic syndrome,Diabetic complications neurological,Diabetic complications,Metab,N
800,1,Brain neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
800,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
801,1,Headache,Headaches NEC,Headaches,Nerv,N
801,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
802,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
802,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
803,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
803,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
803,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
804,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
804,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
805,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
805,2,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,N
805,3,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
805,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
806,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
806,2,Biliary dilatation,Structural and other bile duct disorders,Bile duct disorders,Hepat,N
806,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
806,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
806,5,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
806,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
806,7,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
806,8,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
806,9,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
806,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
806,11,Sleep apnoea syndrome,Breathing abnormalities,Respiratory disorders NEC,Resp,N
807,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
807,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
808,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
808,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
808,3,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
808,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
809,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
809,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
809,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
810,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
810,2,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
811,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
811,2,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
812,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
813,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
813,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
814,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
814,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
814,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
814,4,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
814,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
815,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
815,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
815,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
816,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
816,2,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
816,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
816,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
816,5,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
816,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
816,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
816,8,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
817,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
817,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
818,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
818,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
818,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
819,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
819,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
819,3,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
819,4,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
819,5,Vascular dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
819,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
820,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
820,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
820,3,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
820,4,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
820,5,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
821,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
821,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
822,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
822,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
823,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
824,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
824,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
824,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
824,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
824,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
824,6,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
825,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
825,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
825,3,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
825,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
825,5,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
825,6,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
826,1,Deafness,Hearing losses,Hearing disorders,Ear,N
826,2,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
826,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
827,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
827,2,Motor neurone disease,Motor neurone diseases,Neuromuscular disorders,Nerv,N
827,3,Muscle fatigue,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
828,1,Cardio-respiratory arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
828,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
828,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
828,5,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
829,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
829,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
830,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
830,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
830,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
831,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
831,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
831,3,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
832,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
832,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
832,3,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
833,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
833,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
833,3,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
834,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
834,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
834,3,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
835,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
835,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
835,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
836,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
836,2,Insulin resistant diabetes,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
837,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
837,2,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
837,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
837,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
837,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
838,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
838,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
838,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
839,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
839,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
839,3,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
840,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
840,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
840,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
840,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
840,5,Loss of control of legs,Gait disturbances,General system disorders NEC,Genrl,N
841,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
841,2,Headache,Headaches NEC,Headaches,Nerv,N
841,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
842,1,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
843,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
843,2,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
843,3,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
843,4,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
843,5,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
843,6,Biliary sepsis,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
843,7,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
843,8,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
843,9,Bundle branch block left,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
843,10,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
843,11,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
843,12,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
843,13,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
843,14,Diverticulum,Diverticula,Diverticular disorders,Gastr,N
843,15,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
843,16,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
843,17,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
843,18,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
843,19,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
843,20,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
843,21,Obstructive sleep apnoea syndrome,Breathing abnormalities,Respiratory disorders NEC,Resp,N
843,22,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
843,23,Oliguria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
843,24,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
843,25,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
843,26,Slow speech,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
843,27,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
843,28,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
844,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
845,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
846,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
847,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
847,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
848,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,Y
849,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
849,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
849,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
849,4,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
849,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
849,6,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
850,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
850,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
851,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
851,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
851,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
852,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
852,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
853,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
853,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
854,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
854,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
855,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
855,2,Fluid imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
855,3,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
856,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
856,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
857,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
857,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
858,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
858,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
858,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
859,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
859,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
859,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
859,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
859,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
859,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
860,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
861,1,Abdominal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
861,2,Nonspecific reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
862,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
862,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
862,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
862,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
863,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
864,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
864,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
865,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
866,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
866,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
866,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
867,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
867,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
867,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
867,4,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
868,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
868,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
868,3,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
868,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
868,5,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
868,6,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
869,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
869,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
870,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
871,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
871,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
871,3,Genital rash,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
871,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
871,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
872,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
872,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
872,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
872,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
873,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
873,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
874,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
874,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
875,1,Anal paraesthesia,Anal and rectal signs and symptoms,Anal and rectal conditions NEC,Gastr,N
875,2,Axillary mass,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
875,3,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
875,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
875,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
875,6,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
876,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
877,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
877,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
878,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
878,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
879,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
879,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
879,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
879,4,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
880,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
880,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
881,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
881,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
882,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
882,2,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
883,1,Back disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
883,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
883,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
883,4,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
883,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
884,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
885,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
886,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
886,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
886,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
886,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
886,5,Pancreatic carcinoma metastatic,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
887,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
888,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
888,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
888,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
888,4,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
888,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
889,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
889,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
890,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
891,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
892,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
892,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
892,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
892,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
893,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
893,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
893,3,Induration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
893,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
893,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
894,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
895,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
896,1,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
897,1,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
898,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
898,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
898,3,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
899,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
899,2,Device failure,Device issues NEC,Device issues,Prod,N
900,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
901,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
902,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
902,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
902,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
902,4,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
903,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
903,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
903,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
903,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
904,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
905,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
905,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
906,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
906,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
906,3,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
907,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
907,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
907,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
908,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
908,2,Fracture,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
908,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
908,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
908,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
909,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
910,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
910,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
910,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
911,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
911,2,Colour blindness,Ocular disorders congenital NEC,Eye disorders congenital,Cong,N
911,3,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
911,4,Prostatic disorder,"Prostatic signs, symptoms and disorders NEC",Prostatic disorders (excl infections and inflammations),Repro,N
912,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
912,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
912,3,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
912,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
913,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
913,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
913,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
914,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
914,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
914,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
914,4,Deafness,Hearing losses,Hearing disorders,Ear,N
915,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
915,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
915,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
915,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
915,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
916,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
916,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
917,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
917,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
917,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
917,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
917,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
917,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
918,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
918,2,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
918,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
919,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
919,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
919,3,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
919,4,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
919,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
919,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
919,7,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
919,8,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
919,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
919,10,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
919,11,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
919,12,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
919,13,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
919,14,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
919,15,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
919,16,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
919,17,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
919,18,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
920,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
921,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
921,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
922,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
922,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
922,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
922,4,Product monitoring error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
923,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
923,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
924,1,Drooling,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
924,2,Incorrect product formulation administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
924,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
925,1,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
926,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
927,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
927,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
928,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
928,2,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
929,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
929,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
929,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
929,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
929,5,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
930,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
931,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
931,2,Product lot number issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
932,1,Amyloidoma,Soft tissue neoplasms benign NEC,Soft tissue neoplasms benign,Neopl,N
932,2,Breast mass,Breast disorders NEC,Breast disorders,Repro,N
933,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
934,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
934,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
934,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
935,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
935,2,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
936,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
936,2,Eyelid ptosis,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
936,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
937,1,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
937,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
938,1,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
938,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
938,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
938,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
938,5,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
938,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
938,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
938,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
939,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
940,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
941,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
941,2,Spinal column injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
941,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
942,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
942,2,Gallbladder disorder,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
942,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
943,1,Laryngeal cancer,Laryngeal neoplasms malignant,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
944,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
944,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
944,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
945,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
946,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
946,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
947,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
947,2,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
947,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
947,4,Gastric dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
947,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
948,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
948,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
948,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
948,4,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
948,5,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
949,1,Carotid artery stenosis,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
949,2,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
950,1,Dementia Alzheimer's type,Alzheimer's disease (incl subtypes),Mental impairment disorders,Nerv,N
950,2,Tourette's disorder,Neurological disorders congenital NEC,Neurological disorders congenital,Cong,N
951,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
951,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
952,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
953,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
953,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
954,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
954,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
955,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
955,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
956,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
957,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
958,1,Exomphalos,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
958,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
959,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
959,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
959,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
959,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
959,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
959,6,Ultrasound foetal abnormal,Foetal and neonatal imaging procedures,Foetal and neonatal investigations,Inv,N
960,1,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
960,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
960,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
960,4,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
961,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
961,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
961,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
962,1,Cholestasis of pregnancy,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
962,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
962,3,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
963,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
963,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
963,3,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
963,4,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
964,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
965,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
965,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
965,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
965,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
965,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
965,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
965,7,Pleurisy,Pleural infections and inflammations,Pleural disorders,Resp,N
965,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
965,9,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
965,10,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
966,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
966,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
966,3,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
966,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
966,5,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
967,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
967,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
967,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
968,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
968,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
969,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
970,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
970,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
970,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
970,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
970,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
970,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
970,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
970,8,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
971,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
972,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
972,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
973,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
973,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
974,1,Device colour issue,Device physical property and chemical issues,Device issues,Prod,N
974,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
974,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
974,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
975,1,Hand deformity,Extremity deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
975,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
976,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
977,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
977,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
977,3,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
977,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
977,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
978,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
978,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
978,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
978,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
978,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
979,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
979,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
979,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
979,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
979,5,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
979,6,Prescribed overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
980,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
980,2,Deafness,Hearing losses,Hearing disorders,Ear,N
980,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
980,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
980,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
981,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
981,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
981,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
982,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
982,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
982,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
982,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
983,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
983,2,Emphysema,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
984,1,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
984,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
984,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
984,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
984,5,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
984,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
984,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
984,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
985,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
985,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
985,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
985,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
985,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
985,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
985,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
986,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
987,1,Device failure,Device issues NEC,Device issues,Prod,N
987,2,Device issue,Device issues NEC,Device issues,Prod,N
987,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
987,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
987,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
988,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
988,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
988,3,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
988,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
989,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
990,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
991,1,Bone cancer,Bone neoplasms malignant (excl sarcomas),Skeletal neoplasms malignant and unspecified,Neopl,N
991,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
992,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
993,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
993,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
994,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
994,2,Diabetic metabolic decompensation,Diabetic complications NEC,Diabetic complications,Metab,N
994,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
995,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
995,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
996,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
996,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
996,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
997,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
998,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
998,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
999,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
999,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1000,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1001,1,Administration site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1001,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1001,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1001,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1002,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1002,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1002,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1003,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1003,2,Lumbar spinal stenosis,Spine and neck deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
1003,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1004,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1005,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1005,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1006,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1006,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1006,3,Joint injury,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
1006,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1006,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1006,6,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1007,1,Appendix disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1007,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1007,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1007,4,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1007,5,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
1007,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1008,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1008,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1009,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1009,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1010,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1010,2,Communication disorder,Communications disorders,Communication disorders and disturbances,Psych,N
1010,3,Incorrect drug administration rate,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1010,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1011,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1011,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1012,1,Clavicle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1012,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1013,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1014,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1014,2,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1014,3,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
1015,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1015,2,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
1015,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1015,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1016,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
1016,2,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1016,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1016,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1017,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1017,2,Dyslipidaemia,Lipid metabolism and deposit disorders NEC,Lipid metabolism disorders,Metab,N
1017,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1017,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1017,5,Microalbuminuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1018,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1018,2,Genital swelling,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
1018,3,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
1018,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1018,5,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
1018,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1019,1,Bladder disorder,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
1019,2,Bladder neoplasm,Urinary tract neoplasms unspecified malignancy NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1019,3,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1019,4,Phimosis,Male reproductive tract disorders congenital,Reproductive tract and breast disorders congenital,Cong,N
1019,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
1019,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1019,7,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1020,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1020,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1020,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1020,4,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1020,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1020,6,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1021,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1021,2,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
1021,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1022,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1023,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1024,1,Carotid artery occlusion,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1024,2,Carotid artery occlusion,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1024,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1024,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1025,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1025,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1025,3,Prescribed overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1026,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1026,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1026,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1026,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1026,5,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1026,6,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1026,7,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
1026,8,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1026,9,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1026,10,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
1026,11,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
1026,12,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1026,13,Spinal disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
1026,14,Spinal pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1027,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1027,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1027,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1027,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1027,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1027,6,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
1027,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1028,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1028,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1028,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1028,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1029,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1029,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1030,1,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1031,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1032,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1032,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1032,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1032,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1032,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1033,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1034,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1034,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1034,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1035,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1035,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1036,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1037,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
1037,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1038,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1039,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1039,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1039,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1040,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1040,2,Suspected counterfeit product,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1041,1,Deafness,Hearing losses,Hearing disorders,Ear,N
1042,1,Headache,Headaches NEC,Headaches,Nerv,N
1043,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1043,2,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
1043,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1043,4,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1044,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1044,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1045,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1045,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1045,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1045,4,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1045,5,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
1045,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1045,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1045,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1046,1,Allergic reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1046,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1046,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1046,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1046,5,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1046,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1046,7,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1046,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1047,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1047,2,Pancreatic cyst,Cystic pancreatic disorders,Exocrine pancreas conditions,Gastr,N
1047,3,Splenic abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
1047,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1048,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1048,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1048,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1048,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1049,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1050,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1051,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1051,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1052,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1052,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1052,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1052,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1053,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1054,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1054,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1054,3,Lip blister,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
1054,4,Oral herpes,Herpes viral infections,Viral infectious disorders,Infec,N
1054,5,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1054,6,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
1054,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1054,8,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1054,9,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1054,10,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
1055,1,Ichthyosis,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
1055,2,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
1055,3,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1055,4,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
1055,5,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1056,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1056,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1057,1,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
1057,2,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
1057,3,Impaired driving ability,Disability issues,Lifestyle issues,SocCi,N
1057,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1057,5,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1057,6,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1057,7,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
1057,8,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1057,9,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
1057,10,Walking aid user,Disability issues,Lifestyle issues,SocCi,N
1057,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1058,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1058,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
1058,3,Lip dry,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
1058,4,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1059,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1060,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1060,2,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
1060,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1060,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
1061,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1061,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1062,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1062,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1062,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1062,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1063,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1063,2,Pharyngeal ulceration,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1063,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1064,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1064,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
1064,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1064,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1064,5,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1064,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1065,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1065,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1065,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1065,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1065,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1066,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1066,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1067,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1067,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1068,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1069,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1069,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1069,3,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1069,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1070,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,N
1071,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1071,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
1072,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1072,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1073,1,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1073,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1073,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1073,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1073,5,Reaction to preservatives,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1073,6,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1073,7,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1073,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1074,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1074,2,Drug administered in wrong device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1074,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1075,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1076,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1077,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1077,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1078,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1078,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1078,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1078,4,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1079,1,Coronary artery bypass,Arterial therapeutic procedures (excl aortic),Vascular therapeutic procedures,Surg,N
1079,2,Heart valve operation,Cardiac valve therapeutic procedures,Cardiac therapeutic procedures,Surg,N
1079,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1080,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1080,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1080,3,Pancreatic disorder,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
1080,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1081,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
1082,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
1083,1,Dental paraesthesia,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
1083,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1083,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1083,4,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1083,5,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1083,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1083,7,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1083,8,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
1083,9,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1084,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1085,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1085,2,Cardiogenic shock,Heart failures NEC,Heart failures,Card,N
1085,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1085,4,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
1085,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1085,6,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1085,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1085,8,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1085,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1086,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1087,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1087,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1087,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1088,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1089,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1089,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1090,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1090,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1091,1,Device issue,Device issues NEC,Device issues,Prod,N
1091,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
1092,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1092,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1092,3,Muscle injury,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
1092,4,Pulmonary pain,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1092,5,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
1093,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1094,1,Blood test,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1094,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1095,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1096,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1097,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1098,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1099,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
1099,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
1100,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1101,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1101,2,Grip strength decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1101,3,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1101,4,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1102,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1102,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1102,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1102,4,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1103,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1103,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1104,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1105,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1105,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1105,3,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1105,4,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1105,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1105,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1105,7,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1106,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1106,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1107,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1108,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1108,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1109,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1109,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1109,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1110,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1110,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1111,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1111,2,Device issue,Device issues NEC,Device issues,Prod,N
1112,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
1112,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1112,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1113,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1113,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1114,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1114,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1114,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1114,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1114,5,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1114,6,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1114,7,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1114,8,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1114,9,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1114,10,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
1114,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1114,12,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1114,13,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1114,14,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1114,15,Vascular pain,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1114,16,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1115,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1115,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1116,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1116,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1117,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1117,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1118,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1118,2,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1118,3,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
1118,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1119,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1119,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
1119,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1119,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1119,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1119,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1119,7,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1119,8,Tendon rupture,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
1119,9,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1119,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1120,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1120,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1120,3,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
1121,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1121,2,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
1121,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1122,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1122,2,Impaired driving ability,Disability issues,Lifestyle issues,SocCi,N
1122,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1123,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1124,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1124,2,Euphoric mood,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1124,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1124,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1124,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1124,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1124,7,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1124,8,Vomiting projectile,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1125,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1125,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1126,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1126,2,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
1127,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1127,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1127,3,Functional gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1127,4,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1127,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1127,6,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1127,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1127,8,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1128,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1129,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1130,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1131,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1131,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1132,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1133,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1134,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1135,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1135,2,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
1135,3,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
1135,4,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1135,5,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
1136,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1137,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1137,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1137,3,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1137,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1138,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1138,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1138,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1138,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1138,5,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1139,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1140,1,Allergic reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1140,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1140,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1140,4,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1140,5,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1140,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1140,7,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
1140,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1140,9,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1141,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1142,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1143,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1144,1,Parosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
1145,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1145,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1146,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1146,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1146,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1146,4,Product formulation issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1146,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1147,1,Myopia,Refractive and accommodative disorders,Vision disorders,Eye,N
1148,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1149,1,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1150,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1150,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1150,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1150,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1150,5,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
1151,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1152,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1152,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1153,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1153,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1154,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1154,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1154,3,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1154,4,Suicidal behaviour,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1154,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1155,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1155,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1156,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1156,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1156,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1156,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1156,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1156,6,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1156,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1156,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1156,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1156,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1156,11,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1156,12,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1156,13,Headache,Headaches NEC,Headaches,Nerv,N
1156,14,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1156,15,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1156,16,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1156,17,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1156,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1157,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1158,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1159,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1160,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
1161,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1161,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1161,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1162,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1163,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1164,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1164,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1165,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1165,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1166,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1167,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1168,1,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1169,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1170,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1171,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1172,1,Deafness permanent,Hearing losses,Hearing disorders,Ear,N
1172,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1173,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1174,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1174,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1174,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1174,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1174,5,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1174,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1174,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1174,8,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1174,9,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
1175,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1176,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1177,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1178,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1178,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1178,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1178,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1178,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1178,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1179,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1180,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1180,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1181,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1182,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1182,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1182,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1183,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1183,2,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1183,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1183,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1184,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1185,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1186,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1187,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1188,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1189,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1190,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1191,1,Squamous cell carcinoma of the tongue,Lip and oral cavity neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1192,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1192,2,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1192,3,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
1192,4,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1192,5,Myopia,Refractive and accommodative disorders,Vision disorders,Eye,N
1192,6,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1192,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1192,8,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1192,9,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1192,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1193,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1193,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1194,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1195,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1195,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1196,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
1197,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1197,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1198,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1198,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1199,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1200,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
1200,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1200,3,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1200,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1200,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1200,6,Neuroglycopenia,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1200,7,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1201,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1201,2,Foreign body sensation in eyes,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
1201,3,Genital infection male,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
1201,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
1201,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1201,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1202,1,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
1202,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1203,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1204,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1204,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1205,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
1206,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1207,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1207,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1208,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1208,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1208,3,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
1208,4,Headache,Headaches NEC,Headaches,Nerv,N
1208,5,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1208,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1208,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1208,8,Performance fear,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
1208,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1209,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1209,2,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1210,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1210,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1210,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1211,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1211,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1211,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1212,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1212,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1212,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1213,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1213,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1214,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1214,2,Normal newborn,Normal newborn status,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
1215,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1216,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1217,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1217,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1218,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1219,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1219,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1220,1,Deafness,Hearing losses,Hearing disorders,Ear,N
1220,2,Ear infection viral,Viral infections NEC,Viral infectious disorders,Infec,N
1221,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1222,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1223,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1224,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1224,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1225,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1225,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1225,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1225,4,Deafness,Hearing losses,Hearing disorders,Ear,N
1225,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1225,6,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1225,7,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1225,8,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1225,9,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
1225,10,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1225,11,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1225,12,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1225,13,Limb mass,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1225,14,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1225,15,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1225,16,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1225,17,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1225,18,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1225,19,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1225,20,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1225,21,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
1226,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1226,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1226,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1226,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1226,5,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1227,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1227,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1227,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1228,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1228,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1228,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1228,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1228,5,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
1228,6,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1229,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1230,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1230,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1230,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1230,4,Patella fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1230,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1230,6,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1230,7,Rectal prolapse,Anal and rectal disorders NEC,Anal and rectal conditions NEC,Gastr,N
1231,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1231,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1231,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1232,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1232,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1232,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1232,4,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1233,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1233,2,Gingivitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
1233,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1234,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1234,2,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1234,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1235,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1235,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
1236,1,Addison's disease,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
1236,2,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1236,3,Autoimmune disorder,Autoimmune disorders NEC,Autoimmune disorders,Immun,N
1236,4,Autonomic nervous system imbalance,Autonomic nervous system disorders,Neuromuscular disorders,Nerv,N
1236,5,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1236,6,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1236,7,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1236,8,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1236,9,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1236,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1236,11,Mast cell activation syndrome,Haematological disorders,Haematological disorders NEC,Blood,N
1236,12,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1236,13,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1236,14,Post-acute COVID-19 syndrome,Coronavirus infections,Viral infectious disorders,Infec,N
1236,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1236,16,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1236,17,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1236,18,Wrong technique in device usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1237,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1237,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1237,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1238,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
1238,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1238,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1238,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1239,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1239,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1240,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1240,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1241,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1242,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1243,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1243,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1244,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1244,2,Device failure,Device issues NEC,Device issues,Prod,N
1244,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
1245,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1245,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1246,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1246,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1246,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1246,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1246,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1246,6,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1247,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1247,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
1247,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1247,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1247,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1247,6,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1247,7,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1248,1,Cushing's syndrome,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
1248,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1248,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1249,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1249,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1250,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1250,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1251,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1252,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1252,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1252,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1253,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1253,2,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1254,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
1254,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
1255,1,Myopia,Refractive and accommodative disorders,Vision disorders,Eye,N
1255,2,Retinal tear,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1256,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1256,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1257,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1257,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1258,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1258,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1259,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1259,2,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
1260,1,Vascular dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1261,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1261,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1261,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1261,4,Tooth infection,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
1262,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1262,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1262,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1263,1,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
1264,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1265,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1266,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1267,1,Diabetic mastopathy,Breast disorders NEC,Breast disorders,Repro,N
1268,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1269,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1269,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1270,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1270,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1271,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1271,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1271,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1272,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1272,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1272,3,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1273,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1273,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
1274,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1274,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1274,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
1274,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1274,5,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1275,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1275,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1275,3,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
1275,4,"Sleep disorder due to general medical condition, insomnia type",Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1276,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1276,2,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1276,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1277,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1277,2,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
1277,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1277,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1277,5,Tooth infection,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
1278,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1279,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1280,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
1281,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1282,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1283,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1284,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1285,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1285,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1285,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1285,4,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1285,5,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1285,6,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1286,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1286,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1286,3,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1286,4,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1287,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1287,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1287,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1287,4,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1288,1,False positive investigation result,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1288,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1289,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1289,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1289,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1289,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1289,5,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1289,6,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1290,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1291,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1292,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,Y
1293,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1294,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1295,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1296,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
1297,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1297,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1297,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1297,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
1298,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
1299,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1299,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1299,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1300,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
1301,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1301,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1302,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1303,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1304,1,Hypertrophic cardiomyopathy,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
1304,2,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1304,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1304,4,Pancreatic failure,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
1305,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1305,2,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1306,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1307,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1307,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1307,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1308,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
1308,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1308,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1309,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1310,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1310,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1311,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
1311,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1312,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1312,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1313,1,Deafness,Hearing losses,Hearing disorders,Ear,N
1314,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1314,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1315,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1316,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1316,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1316,3,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
1316,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1317,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1317,2,Diabetic foot infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
1317,3,Generalised anxiety disorder,Anxiety disorders NEC,Anxiety disorders and symptoms,Psych,N
1317,4,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1317,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1317,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1317,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1317,8,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1318,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1318,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1319,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1319,2,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1319,3,Wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1320,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1320,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1321,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1321,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
1322,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1322,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1323,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1324,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1325,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1325,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1326,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1326,2,Fibromyalgia,Muscle pains,Muscle disorders,Musc,N
1326,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1327,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1327,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1328,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1329,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1329,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1329,3,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
1330,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1330,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1330,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1331,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1331,2,Deafness,Hearing losses,Hearing disorders,Ear,N
1332,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1332,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1332,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1333,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1334,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1334,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1334,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1334,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1334,5,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1335,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1335,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1335,3,Poor quality product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1336,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1337,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1337,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1337,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1337,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1337,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1338,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
1338,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1338,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1339,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
1339,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1339,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1339,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1340,1,Hypermetropia,Refractive and accommodative disorders,Vision disorders,Eye,N
1341,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1341,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1342,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1342,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
1342,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1342,4,Wrong patient,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1343,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1343,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1344,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
1345,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1345,2,Wrong dose,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1346,1,Blood insulin decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1347,1,Blood cholesterol abnormal,Cholesterol analyses,Lipid analyses,Inv,N
1347,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1347,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1347,4,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
1348,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1348,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1348,3,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1348,4,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1348,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1348,6,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
1348,7,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1348,8,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1348,9,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1349,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1350,1,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1351,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1351,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1352,1,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1352,2,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
1353,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1353,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1353,3,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1353,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1353,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1353,6,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
1353,7,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
1353,8,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1354,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1355,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1355,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1356,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1357,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1357,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1357,3,Insulin C-peptide decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1357,4,Insulinoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
1357,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1358,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1358,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1358,3,Insulin C-peptide decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1358,4,Insulin autoimmune syndrome,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1358,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1359,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1359,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1359,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1360,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1361,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1361,2,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1362,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1362,2,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
1362,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1362,4,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1362,5,Postural orthostatic tachycardia syndrome,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1362,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1363,1,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
1364,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1365,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1365,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1366,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1367,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1367,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1367,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1368,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1369,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
1370,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1371,1,Blood insulin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
1372,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1372,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1372,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1372,4,Product contamination,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1373,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1373,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1374,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1375,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1375,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1376,1,Pelvic infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1377,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1377,2,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1377,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1377,4,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1377,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1378,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1378,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1378,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1378,4,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1379,1,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1379,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1379,3,Sedation,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1379,4,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1380,1,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1381,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1382,1,Eye inflammation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
1382,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1383,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1383,2,Device operational issue,Device operational issues NEC,Device issues,Prod,N
1383,3,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1384,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1384,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1384,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1385,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1386,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1386,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1387,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1387,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1388,1,Allergic reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1389,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1389,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1389,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1389,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
